Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Processa Pharmaceuticals, Inc. PCSA
$0.68
+$0.02 (2.66%)
На 18:03, 12 мая 2023
+1 223.53%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
17190320.00000000
-
week52high
3.83
-
week52low
0.36
-
Revenue
0
-
P/E TTM
0
-
Beta
0.11868500
-
EPS
-1.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 19 апр 2022 г. | |
| Oppenheimer | Outperform | 03 авг 2021 г. | |
| Oppenheimer | Outperform | 02 авг 2021 г. | |
| Craig-Hallum | Buy | 28 окт 2020 г. | |
| Maxim Group | Buy | Buy | 12 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Yorke Justin W | A | 30000 | 30000 | 01 янв 2023 г. |
| Lin Patrick | A | 440328 | 40690 | 01 янв 2023 г. |
| Lin Patrick | A | 399638 | 55107 | 01 янв 2023 г. |
| Guy Wendy | A | 440328 | 40690 | 01 янв 2023 г. |
| Guy Wendy | A | 399638 | 55107 | 01 янв 2023 г. |
| Stanker James H | D | 518431 | 96150 | 01 янв 2023 г. |
| Stanker James H | D | 422281 | 69667 | 01 янв 2023 г. |
| Floyd Robert Michael | A | 440328 | 40690 | 01 янв 2023 г. |
| Floyd Robert Michael | A | 399638 | 55107 | 01 янв 2023 г. |
| Young David | A | 424373 | 24030 | 01 янв 2023 г. |
Новостная лента
Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 20:55
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Participants Francois Brisebois - Oppenheimer Naz Rahman - Maxim Group Operator Greetings, and welcome to Processa Pharmaceuticals third-quarter 2022 earnings call and corporate update. At this time, all participants are in a listen-only mode.
Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
GlobeNewsWire
02 ноя 2022 г. в 08:30
HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.
Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
GlobeNewsWire
07 сент 2022 г. в 08:30
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that Dr. Dr. David Young, Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 14, 2022.
Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
14 авг 2022 г. в 06:13
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants James Stanker - Chief Financial Officer David Young - President and Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer & Co. Inc. Naz Rahman - Maxim Group LLC Operator Good afternoon, ladies and gentlemen, and welcome to the Processa Pharmaceuticals Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
GlobeNewsWire
05 авг 2022 г. в 15:00
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on August 11, 2022, at 4:30 p.m. EST to discuss its second quarter 2022 results and provide an update on its clinical pipeline.